SG11201803066VA - Dihydroimidazopyrazinone derivatives useful in the treatment of cancer - Google Patents
Dihydroimidazopyrazinone derivatives useful in the treatment of cancerInfo
- Publication number
- SG11201803066VA SG11201803066VA SG11201803066VA SG11201803066VA SG11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- derivatives useful
- dihydroimidazopyrazinone
- dihydroimidazopyrazinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252726P | 2015-11-09 | 2015-11-09 | |
| US201662401351P | 2016-09-29 | 2016-09-29 | |
| PCT/EP2016/076932 WO2017080979A1 (en) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803066VA true SG11201803066VA (en) | 2018-05-30 |
Family
ID=57241113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803066VA SG11201803066VA (en) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9902731B2 (lt) |
| EP (1) | EP3374359B1 (lt) |
| JP (1) | JP6877423B2 (lt) |
| KR (1) | KR20180074788A (lt) |
| CN (1) | CN108349983B (lt) |
| AU (1) | AU2016351813B2 (lt) |
| BR (1) | BR112018008397B1 (lt) |
| CA (1) | CA3003549A1 (lt) |
| CL (1) | CL2018001226A1 (lt) |
| CO (1) | CO2018004857A2 (lt) |
| CR (1) | CR20180316A (lt) |
| CY (1) | CY1123627T1 (lt) |
| DK (1) | DK3374359T3 (lt) |
| EA (1) | EA038028B1 (lt) |
| ES (1) | ES2780650T3 (lt) |
| HK (1) | HK1256283A1 (lt) |
| HR (1) | HRP20200342T1 (lt) |
| IL (1) | IL258953A (lt) |
| LT (1) | LT3374359T (lt) |
| ME (1) | ME03770B (lt) |
| MX (1) | MX2018005725A (lt) |
| MY (1) | MY197626A (lt) |
| NI (1) | NI201800058A (lt) |
| PE (1) | PE20181288A1 (lt) |
| PH (1) | PH12018500987A1 (lt) |
| PL (1) | PL3374359T3 (lt) |
| PT (1) | PT3374359T (lt) |
| RS (1) | RS60155B1 (lt) |
| SG (1) | SG11201803066VA (lt) |
| SI (1) | SI3374359T1 (lt) |
| SV (1) | SV2018005687A (lt) |
| TN (1) | TN2018000119A1 (lt) |
| TW (1) | TWI730012B (lt) |
| WO (1) | WO2017080979A1 (lt) |
| ZA (1) | ZA201803742B (lt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA47013A (fr) | 2015-10-21 | 2018-08-29 | Otsuka Pharma Co Ltd | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase |
| PL3374359T3 (pl) * | 2015-11-09 | 2020-06-29 | Astrazeneca Ab | Pochodne dihydroimidazopirazynonu użyteczne w leczeniu nowotworu |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| JP7352981B2 (ja) * | 2018-10-10 | 2023-09-29 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用 |
| KR20210145773A (ko) | 2019-03-28 | 2021-12-02 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 티에노헤테로고리형 유도체, 이의 제조 방법 및 이의 의약적 용도 |
| JP2022534224A (ja) | 2019-05-24 | 2022-07-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用 |
| TW202134242A (zh) | 2019-12-05 | 2021-09-16 | 瑞典商阿斯特捷利康公司 | 用於生產式(i)之方法及中間體 |
| US20230072937A1 (en) * | 2019-12-06 | 2023-03-09 | Medshine Discovery Inc. | Thiazololactam compound as erk inhibitor and use thereof |
| US20230331731A1 (en) | 2020-09-29 | 2023-10-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of pyrrolo heterocyclic derivative and preparation method therefor |
| CN117529321A (zh) * | 2021-06-18 | 2024-02-06 | 上海德琪医药科技有限公司 | Erk抑制剂和kras抑制剂的组合及其用途 |
| WO2022268065A1 (en) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Compounds as erk inhibitors |
| WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2023081860A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Triazine amino derivatives for treating sca3 |
| WO2023212231A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2023220433A1 (en) | 2022-05-12 | 2023-11-16 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2024006971A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US7485640B2 (en) * | 2002-11-06 | 2009-02-03 | Merck Sharp & Dohme Limited | Imidazopyrazinones as GABA-A receptor anxiolytics |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| EP2132178B1 (en) * | 2006-12-20 | 2015-08-19 | Merck Sharp & Dohme Corp. | Jnk inhibitors |
| MY170715A (en) * | 2010-12-22 | 2019-08-27 | Janssen Pharmaceutica Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| EP2906562B1 (en) * | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| JP2013166727A (ja) * | 2012-02-16 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロイミダゾピラジノン誘導体 |
| SG11201405356QA (en) | 2012-03-01 | 2014-11-27 | Array Biopharma Inc | Serine/threonine kinase inhibitors |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| CN106029672B (zh) * | 2013-12-06 | 2019-03-29 | 基因泰克公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| CN105980387B (zh) * | 2013-12-30 | 2019-04-19 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| SI3129025T1 (sl) | 2014-04-09 | 2019-08-30 | Genentech, Inc. | Postopek za izdelavo zdravil |
| US10412619B2 (en) * | 2014-11-14 | 2019-09-10 | Qualcomm Incorporated | Buffer status report for eDCS |
| WO2016162325A1 (en) * | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| US10479791B2 (en) | 2015-06-03 | 2019-11-19 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as ERK inhibitors |
| US10238657B2 (en) | 2015-06-03 | 2019-03-26 | Js Innopharm (Shanhai) Ltd. | Heterocyclic compounds for treating psoriasis |
| PL3374359T3 (pl) * | 2015-11-09 | 2020-06-29 | Astrazeneca Ab | Pochodne dihydroimidazopirazynonu użyteczne w leczeniu nowotworu |
-
2016
- 2016-11-08 PL PL16791420T patent/PL3374359T3/pl unknown
- 2016-11-08 CA CA3003549A patent/CA3003549A1/en active Pending
- 2016-11-08 KR KR1020187016091A patent/KR20180074788A/ko not_active Application Discontinuation
- 2016-11-08 SI SI201630668T patent/SI3374359T1/sl unknown
- 2016-11-08 JP JP2018522784A patent/JP6877423B2/ja active Active
- 2016-11-08 CN CN201680064567.2A patent/CN108349983B/zh active Active
- 2016-11-08 DK DK16791420.9T patent/DK3374359T3/da active
- 2016-11-08 EA EA201891063A patent/EA038028B1/ru unknown
- 2016-11-08 US US15/345,537 patent/US9902731B2/en active Active
- 2016-11-08 ES ES16791420T patent/ES2780650T3/es active Active
- 2016-11-08 TN TNP/2018/000119A patent/TN2018000119A1/en unknown
- 2016-11-08 PT PT167914209T patent/PT3374359T/pt unknown
- 2016-11-08 LT LTEP16791420.9T patent/LT3374359T/lt unknown
- 2016-11-08 MX MX2018005725A patent/MX2018005725A/es active IP Right Grant
- 2016-11-08 EP EP16791420.9A patent/EP3374359B1/en active Active
- 2016-11-08 RS RS20200392A patent/RS60155B1/sr unknown
- 2016-11-08 MY MYPI2018000675A patent/MY197626A/en unknown
- 2016-11-08 CR CR20180316A patent/CR20180316A/es unknown
- 2016-11-08 WO PCT/EP2016/076932 patent/WO2017080979A1/en active Application Filing
- 2016-11-08 PE PE2018000611A patent/PE20181288A1/es unknown
- 2016-11-08 ME MEP-2020-72A patent/ME03770B/me unknown
- 2016-11-08 BR BR112018008397-6A patent/BR112018008397B1/pt active IP Right Grant
- 2016-11-08 SG SG11201803066VA patent/SG11201803066VA/en unknown
- 2016-11-08 AU AU2016351813A patent/AU2016351813B2/en active Active
- 2016-11-08 TW TW105136236A patent/TWI730012B/zh active
-
2018
- 2018-01-18 US US15/873,965 patent/US10202391B2/en active Active
- 2018-04-26 IL IL258953A patent/IL258953A/en active IP Right Grant
- 2018-05-03 NI NI201800058A patent/NI201800058A/es unknown
- 2018-05-07 CO CONC2018/0004857A patent/CO2018004857A2/es unknown
- 2018-05-07 PH PH12018500987A patent/PH12018500987A1/en unknown
- 2018-05-07 SV SV2018005687A patent/SV2018005687A/es unknown
- 2018-05-07 CL CL2018001226A patent/CL2018001226A1/es unknown
- 2018-06-06 ZA ZA2018/03742A patent/ZA201803742B/en unknown
- 2018-11-30 HK HK18115347.8A patent/HK1256283A1/zh unknown
-
2020
- 2020-02-28 HR HRP20200342TT patent/HRP20200342T1/hr unknown
- 2020-04-02 CY CY20201100314T patent/CY1123627T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
| HK1249524A1 (zh) | 用於治療血載癌症的免疫檢查點抑制劑 | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| IL259996A (en) | Combinations for cancer treatment | |
| LT3122358T (lt) | Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| IL251903A0 (en) | Epilimod for use in the treatment of colon cancer | |
| EP4043567C0 (en) | METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER | |
| IL265268A (en) | Combinations including 196 abx for sabertan treatment | |
| IL262143A (en) | Improvements in cancer treatment | |
| SG10202001388YA (en) | Use of ureidomustine (bo-1055) in cancer treatment | |
| HK1251794A1 (zh) | 癌症治療 | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB201522433D0 (en) | Cancer treatment | |
| GB201410695D0 (en) | Uses of oligouronates in cancer treatment |